Table 1.

Patient characteristics at baseline.

Patient number	Age in years	Gender	Medication	MADRS-Sa	Duration of BD-IIbin years
1	66	Female	valproate, olanzapinec, fluoxetine, zopiclone (prnd)	19	14
2	31	Female	aripiprazole, duloxetine, propiomazine (prn), zolpidem (prn), levothyroxine	11	6
3	49	Female	lithium sulfate, melatonin, levothyroxine, orlistat	12	31
4	49	Male	valproate, lamotrigine, olanzapinec, venlafaxine	8	8
5e	24	Female	lamotrigine, olanzapinec, sertraline	18	2
6e	32	Female	lamotrigine, fluoxetine, pregabalin, oxazepam (prn), zopiclone (prn), acetaminophen, pramipexole	20	3
7e	56	Female	lithium sulfate, propiomazine	10	30

^ascore on the Montgomery-Åsberg Depression Rating Scale—Self-rated (MADRS-S) at baseline screening

^byears since first diagnosed with bipolar disorder type II (BD-II)

^cThe Olanzapine dosage for patient 1 was 5 mg hs (at bedtime), and for patients 4 and 5 was only 2.5 mg hs, thus hardly interfering with daytime cognition

^dprn: as needed

^epatients 5, 6, and 7 dropped out during baseline